Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV-1 Shedding among Women Initiating Treatment
Date
2010Author
Graham, Susan M
Masese, Linnet
Gitau, Ruth
Jalalian-Lechak, Zahra
Richardson, Barbra A
Peshu, Norbert
Mandaliya, Kishor
Kiarie, James N
Jaoko, Walter
Ndinya-Achola, Jeckoniah
Overbaugh, Julie
McClelland, R Scott
Language
enMetadata
Show full item recordAbstract
Persistent genital human immunodeficiency virus type 1 (HIV-1) shedding among women receiving antiretroviral therapy (ART) may present a transmission risk. We investigated the associations between genital HIV-1 suppression after ART initiation and adherence, resistance, pretreatment CD4 cell count, and hormonal contraceptive use. First-line ART was initiated in 102 women. Plasma and genital HIV-1 RNA levels were measured at months 0, 3, and 6. Adherence was a strong and consistent predictor of genital HIV-1 suppression (P < .001), whereas genotypic resistance was associated with higher vaginal HIV-1 RNA level at month 6 (P = .04). These results emphasize the importance of adherence to optimize the potential benefits of ART for reducing HIV-1 transmission risk.
Citation
J Infect Dis. (2010) 202 (10): 1538-1542. doi: 10.1086/656790Publisher
University of Nairobi
Collections
- Faculty of Health Sciences (FHS) [10385]